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Ghrelin inhibits insulin secretion partly via induction of IA-2b. However, the orexigenic effect of
ghrelin is mediated by the AMP-activated protein kinase (AMPK)–uncoupling protein 2 (UCP2) path-
way. Here, we demonstrate that ghrelin’s inhibitory effect on insulin secretion also occurs through
the AMPK-UCP2 pathway. Ghrelin increased AMPK phosphorylation and UCP2 mRNA expression in
MIN6 insulinoma cells. Overexpression or downregulation of UCP2 attenuated or enhanced insulin
secretion, respectively. Furthermore, AMPK activator had a similar effect to ghrelin on UCP2 and
insulin secretion in MIN6 cells. In conclusion, ghrelin’s inhibitory effect on insulin secretion is partly
mediated by the AMPK-UCP2 pathway, which is independent of the IA-2b pathway.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ghrelin, the only circulating orexigenic hormone, was ﬁrst iden-
tiﬁed in rat stomach as an endogenous ligand of growth-hormone
secretagogue receptor (GHSR) [1]. Although ghrelin is mainly pro-
duced and secreted from the stomach [1], pancreas also express
ghrelin [2,3] and GHSR [4], as well as the pancreatic b cell line
MIN6 cells [5]. In addition, ghrelin concentration is eight times
higher in pancreatic veins than in pancreatic artery [6], suggesting
that ghrelin is produced and released from islet cells and might act
on b cells via autocrine and/or paracrine manner.
Besides modulating energy homeostasis by increasing food in-
take, body weight and adiposity [7,8], ghrelin was also suggested
affecting pancreatic b cell function. Administration of ghrelin re-
sulted in a decrease in plasma insulin and an increase in plasma
glucose levels [9]. Overexpression of ghrelin led to inhibition of
glucose-stimulated insulin secretion (GSIS) and deleting the genechemical Societies. Published by E
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Nishi).of ghrelin or GHSR resulted in lower blood glucose [10] in mice.
We have reported that ghrelin inhibited insulin secretion via
inducing IA-2b [5]. But the intrinsic mechanism of this has not
been investigated sufﬁciently.
AMP-activated protein kinase (AMPK) plays an important role
in glucose homeostasis. It is well known that activation of AMPK
suppresses GSIS in b cell lines [11] and isolated islets [12]. Ghrelin
regulates AMPK activity in various tissues in a tissue-speciﬁc man-
ner [13–15]. However, there is no report about how ghrelin affect
AMPK activity in b cells till now.
Ghrelin also enhanced uncoupling protein 2 (UCP2) expression
in the hypothalamus [13], liver [14] and white adipose tissue [8].
The orexigenic effect of ghrelin on the hypothalamus was demon-
strated to be a UCP2-dependent action via AMPK [13]. Ghrelin-
deﬁcient mice showed reduced UCP2 mRNA expression and en-
hanced GSIS [16]. Overexpression of UCP2 in rat islets decreased
insulin secretion [17]. Gonzalez-Barroso et al. reported an impaired
activity of UCP2 mutants which was related with human congeni-
tal hyperinsulinism [18]. Therefore, ghrelin may affect insulin
secretion through AMPK-UCP2 pathway.
2. Materials and methods
2.1. Cell culture and reagents
MIN6 cells were maintained in DMEM containing 25 mmol/l
glucose, 10% FBS, and antibiotics (Invitrogen, Carlsbad, CA) atlsevier B.V. All rights reserved.
1504 Y. Wang et al. / FEBS Letters 584 (2010) 1503–150837 C in 5% CO2. Ghrelin (acylated form) and desacyl-ghrelin were
bought from Peptide Ins. (Osaka, Japan). 5-Aminoimidazole-4-car-
boxamide-1-b-D-ribofuranoside (AICAR) was purchased from Sig-
ma (St. Louis, MO). Antibodies for phospho-AMPK and total
AMPK were obtained from Cell Signaling Technology (Danvers,
MA).
2.2. Plasmid construction, RNA interference and transfection
Plasmids encoding mouse IA-2b were constructed as described
elsewhere [5]; full length UCP2 clone obtained from the cDNA of
MIN6 cells was subcloned into the plasmid pcDNA 3.1 (Invitrogen)
at the EcoRI–NotI sites. Constructed plasmids were transfected to
MIN6 cells using FuGENE6 Transfection Reagent (Roche Diagnos-
tics, Mannheim, Germany). The pcDNA 3.1 vector was used as con-
trol. Short-interfering RNA (siRNA) of UCP2 was obtained from
QIAGEN (Valencia, CA) and transfected into MIN6 cells by RNAiFect
Transfection Reagent (QIAGEN). Negative-control siRNA (accompa-
niment to RNAiFect) was used as control.
2.3. RT-PCR and quantitative PCR
Total RNA derived fromMIN6 cells was reverse-transcribed into
cDNA and expression levels of UCP2 and IA-2b mRNA were ana-
lyzed by quantitative real-time PCR (QT-PCR) as described before0
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Fig. 1. Effect of ghrelin on UCP2 expression and AMPK activity in MIN6 cells. MIN6 cells
10 nmol/l ghrelin; (B) with or without 10 nmol/l desacyl-ghrelin. (A and B) UCP2 mRNA ex
the values observed with cells that were not stimulated by ghrelin or desacyl-ghrelin. (C
Western blot analysis. The data presented is representative of three independent experim
absorbance at 450 nm and normalized to the protein content of the samples. All values a
**P < 0.01 versus without ghrelin or desacyl-ghrelin).[5]. Primer pairs and FAM-conjugated probes for UCP2 were pur-
chased from Applied Biosystems (Assay ID: Mm00627599_ml).
Data were calculated as copy number of each mRNA relative to
ARP as an internal control.
2.4. Western blot analysis and AMPK activity
Cultured cells were washed twice with ice-cold PBS and
resuspended immediately in lysis buffer containing 1% Non-diet
P-40, 140 mmol/l NaCl, 20 mmol/l Tris–HCl (pH8.0), 1 mmol/l
MgCl2, 1 mmol/l CaCl2, 1 mmol/l DTT, 10% glycerol, 0.5 mmol/l
Na3VO4, 20 mmol/l pyrophosphate Na, 1 mmol/l PMSF, 5 mmol/l
NaF, 1 mmol/l aprotinin, 4 mmol/l leupeptin, 5 mmol/l pepstatin.
Protein content in the lysate was measured using the Bio-Rad
Protein Assay kits (Bio-RAD, Hercules, CA). Protein samples
(25 lg) were subjected to SDS–PAGE and transferred to nitrocel-
lulose membrane then immunoblotted by using the phospho-
AMPK and total AMPK antibodies. The proteins bound to anti-
bodies were detected using horseradish peroxidase-conjugated
anti-rabbit IgG (Biosource Int., Camarillo, CA) and visualized by
using enhanced chemiluminescence detection system (MILLI-
PORE, Billerica, MA).
AMPK activity in the samples was assessed using the AMPK ki-
nase assay kit (Cyclex, Nagano, Japan) according to the manufac-
turer’s instructions.0
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The GSIS experiments were carried out as described before [5].
In short, MIN6 cells were incubated with indicated concentrations
of glucose in the presence or absence of 10 nmol/l ghrelin or
0.4 mmol/l AICAR for one hour. Insulin content in the supernatant
was quantiﬁed by an ELISA kit (Linco Research, St. Charles, MO)
and normalized by the protein contents of the cell lysate. Data
were expressed as ng/mg protein. To study the effect of UCP2 on
insulin secretion, MIN6 cells were transfected with pcDNA3.1
UCP2 or UCP2 siRNA and the control vector or control siRNA
24hours before glucose and ghrelin stimulation.
2.6. Statistical analysis
Data are expressed as means ± S.E. for at least three indepen-
dent experiments in duplicates. Variances in different groups were
analyzed by Student’s t-test or one-way ANOVA for unpaired com-
parisons. P value <0.05 was accepted as signiﬁcant.
3. Results
3.1. Ghrelin upregulates UCP2 and activates AMPK in MIN6 cells
After the administration of ghrelin for 1 h at high glucose con-
dition, UCP2 mRNA expression levels in MIN6 cells were upregu-
lated dose-dependently (Fig. 1A). However, desacyl-ghrelin did
not show any effect on UCP2 (Fig. 1B). Our data are consistent withControl UCP2 
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Fig. 2. Effect of UCP2 overexpression or downregulation on insulin secretion. (A and B)
were treated 1 h with (A) indicated concentrations of glucose (3.3, 5.5, 8.3, 11.1, 22.2 mm
cells transfected with UCP2 siRNA or control siRNA were treated as described in (B). Insul
cell lysate. All values are expressed as means ± S.E. of three independent experiments (n
versus control vector or control siRNA transfection without ghrelin).the view that the acylation is essential for the bioactivity of ghrelin
[1]. Ghrelin treatment also induced AMPK phosphorylation
(Fig. 1C) as well as AMPK activity (Fig. 1D).
3.2. Effect of UCP2 overexpression or downregulation on insulin
secretion
Overexpression of UCP2 attenuated GSIS in MIN6 cells with lit-
tle or no effect on basal insulin secretion (Fig. 2A). Administration
of ghrelin to the cells transfected with UCP2 for 1 h seemed to de-
crease GSIS further, but without statistical signiﬁcance (Fig. 2B). On
the other hand, downregulation of UCP2 by siRNA technique aug-
mented GSIS in MIN6 cells and abolished ghrelin’s inhibitory effect
on GSIS (Fig. 2C).
3.3. AICAR elevates UCP2 expression and inhibits GSIS in MIN6 cells
Administration of AICAR (AMPK activator) for 1 h increased
UCP2 mRNA expression levels dose-dependently (Fig. 3A), suggest-
ing that AMPK might act upstream of UCP2 to mediate the effect of
ghrelin on UCP2. AICAR suppressed the insulin secretion that was
induced by 22.2 mmol/l glucose but left the basal insulin secretion
intact (Fig. 3B), mimicking the effect of ghrelin. Administration of
AICAR and ghrelin together to MIN6 cells decreased GSIS further
in contrast to AICAR (P < 0.05) or ghrelin (not statistical signiﬁcant)
alone (Fig. 3C). Thus AMPK activation by ghrelin might play a role
in the inhibitory effect of ghrelin on insulin secretion by lying be-
tween ghrelin and UCP2 and acting as a signal transmitter.#*
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As we have reported that ghrelin inhibits GSIS via inducing
IA-2b [5], we assumed that a crosstalk existed between the
AMPK–UCP2 pathway and IA-2b pathway. But AMPK activation
by AICAR failed to change IA-2b mRNA expression levels
(Fig. 4A) in MIN6 cells. Moreover, overexpression of UCP2 did
not affect IA-2b mRNA expression levels (Fig. 4B), and vice versa
(Fig. 4C). These data suggest that there is not interaction be-
tween the two pathways.
4. Discussion
This study was designed to investigate the molecular mecha-
nism of ghrelin’s inhibitory effect on GSIS in pancreatic b cells. In
this study, we found that ghrelin (acylated form) activates
AMPK–UCP2 pathway in MIN6 cells. Furthermore, this pathway
modulates GSIS. Therefore, this pathway plays a part in the inhib-
itory effect of ghrelin on insulin secretion.
Recently, UCP2 was suggested to regulate insulin secretion in
many reports. We reported that the UCP2 promoter polymorphism
866G/A was related with GSIS and requirement of insulin therapyin Japanese type 2 diabetes [19]. Here by modulating UCP2 expres-
sion levels, we showed that UCP2 is closely related with insulin
secretion and interfere with ghrelin’s impact to MIN6 cells.
UCP2-deﬁcient mice had higher islet ATP levels and increased
GSIS [20]. On the contrary, overexpression of UCP2 in b cells abol-
ished the inhibitory effect of glucose on KATP channel activity and
diminished the glucose-stimulated increase of cytosolic Ca2+ con-
centration and insulin secretion [21].
AMPK activation increases the expression of UCP2 in liver [22],
skeletal muscle [23], hypothalamus [13], and endothelial cells [24].
Here we found that activation of AMPK by AICAR upregulates UCP2
mRNA expression in MIN6 cells as well.
The mechanism through which AMPK increases UCP2 expres-
sion remains unclear. Peroxisome proliferator-activated receptor
(PPAR) family, PPAR-a and PPAR-c coactivator-1-alpha (PGC-1a)
which have been described as regulators of mitochondrial biogen-
esis may be the possible mediators. It was suggested recently that
the NAD+-dependent type III deacetylase SIRT1 might lie between
AMPK and PGC-1a [25]. On the other hand, reactive oxygen species
(ROS) may be another choice. AMPK activation in b cells increased
production of ROS, and increased ROS then promote UCP2 tran-
scription and activity [13,26].
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expression, AMPK activated by AICAR inhibited GSIS as well. As
ghrelin activated AMPK induces UCP2 expression, it is possible that
ghrelin upregulates UCP2 expression and inhibits GSIS via AMPK
activation.
We noticed that AICAR and ghrelin together has a stronger ef-
fect on GSIS than AICAR or ghrelin alone, suggesting that they
might have additive effect and might activate AMPK which was
inhibited by high concentration of glucose [27] furthermore than
one reagent alone. But this additive effect is only signiﬁcant com-
pared with AICAR alone, which could be explained by the existence
of other pathways of ghrelin on insulin secretion such as IA-2b [5].
We previously reported that ghrelin inhibited insulin secretion
via inducing IA-2b. However, neither did overexpression of UCP2
affect IA-2b mRNA expression nor did overexpression of IA-2b af-
fect UCP2 mRNA expression. Likewise, AMPK activation by AICAR
did not change IA-2b expression. Then it seems that IA-2b lies inde-
pendent of the ghrelin–AMPK–UCP2 pathway. Therefore, ghrelin
has intricate mechanisms that include different pathways in regu-
lating insulin secretion.
5. Conclusions
Ghrelin activates AMPK and upregulates UCP2 mRNA expres-
sion in MIN6 cells. Furthermore, Ghrelin’s inhibitory effect on insu-
lin secretion is partly mediated by AMPK–UCP2 pathway which is
independent of IA-2b pathway.
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